OncoMatch/Clinical Trials/NCT05076942
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
Is NCT05076942 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Cisplatin for vulvar cancer.
Treatment: Cisplatin — Vulvar cancer patients with SN-metastasis \> 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Cervical Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: pelvic radiotherapy
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5 x 10^9 /l; platelet count ≥ 100 x 10^9 /l
Kidney function
creatinine clearance ≥ 40 ml/min measured by the cockroft gault formula
Liver function
total bilirubin < 1.25 x uln; ast and alt ≤ 2.5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, California
- Mount Sinai Medical Center · Miami Beach, Florida
- Baystate Medical Center · Springfield, Massachusetts
- Spectrum Health at Butterworth Campus · Grand Rapids, Michigan
- Munson Medical Center · Traverse City, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05076942 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pelvic radiotherapy disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages